 Mark Gerich
Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 9 | 2022 | 196 | 1.940 |
Why?
| | Medical Marijuana | 4 | 2017 | 97 | 1.440 |
Why?
| | Inflammatory Bowel Diseases | 9 | 2022 | 288 | 1.370 |
Why?
| | Immunosuppressive Agents | 5 | 2020 | 651 | 1.350 |
Why?
| | Gastrointestinal Diseases | 3 | 2016 | 182 | 1.310 |
Why?
| | Thalidomide | 2 | 2015 | 28 | 0.970 |
Why?
| | Colitis, Ulcerative | 5 | 2020 | 105 | 0.920 |
Why?
| | Colitis | 8 | 2020 | 226 | 0.830 |
Why?
| | Intestinal Mucosa | 7 | 2021 | 528 | 0.670 |
Why?
| | Drug Resistance | 1 | 2013 | 158 | 0.410 |
Why?
| | Salvage Therapy | 1 | 2013 | 126 | 0.410 |
Why?
| | Tacrolimus | 1 | 2013 | 135 | 0.400 |
Why?
| | Intestines | 3 | 2021 | 322 | 0.400 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 19 | 0.380 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.380 |
Why?
| | Intestinal Neoplasms | 1 | 2011 | 24 | 0.380 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1138 | 0.370 |
Why?
| | Antiporters | 2 | 2021 | 18 | 0.360 |
Why?
| | Mercaptopurine | 1 | 2010 | 15 | 0.360 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 43 | 0.360 |
Why?
| | Allopurinol | 1 | 2010 | 55 | 0.350 |
Why?
| | Precision Medicine | 1 | 2013 | 340 | 0.350 |
Why?
| | Gastrointestinal Microbiome | 3 | 2022 | 502 | 0.350 |
Why?
| | Enzyme Inhibitors | 2 | 2010 | 752 | 0.340 |
Why?
| | Acidosis | 2 | 2021 | 87 | 0.330 |
Why?
| | Spondylarthritis | 2 | 2021 | 36 | 0.330 |
Why?
| | Algorithms | 3 | 2020 | 1488 | 0.330 |
Why?
| | Colon | 2 | 2020 | 233 | 0.310 |
Why?
| | Tryptophan | 2 | 2021 | 135 | 0.300 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 679 | 0.290 |
Why?
| | Ileitis | 2 | 2021 | 26 | 0.290 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1268 | 0.280 |
Why?
| | Dextran Sulfate | 5 | 2020 | 70 | 0.260 |
Why?
| | Endocannabinoids | 2 | 2017 | 37 | 0.250 |
Why?
| | Adenocarcinoma | 1 | 2011 | 795 | 0.240 |
Why?
| | Legislation, Drug | 2 | 2016 | 78 | 0.240 |
Why?
| | United States Food and Drug Administration | 2 | 2016 | 172 | 0.230 |
Why?
| | Humans | 33 | 2023 | 115042 | 0.220 |
Why?
| | Microbiota | 2 | 2022 | 648 | 0.210 |
Why?
| | Metabolomics | 3 | 2022 | 527 | 0.200 |
Why?
| | Infliximab | 3 | 2020 | 94 | 0.190 |
Why?
| | Inflammation | 4 | 2019 | 2485 | 0.180 |
Why?
| | Ustekinumab | 1 | 2020 | 12 | 0.180 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 127 | 0.180 |
Why?
| | Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2020 | 4 | 0.180 |
Why?
| | Killer Cells, Natural | 1 | 2023 | 383 | 0.180 |
Why?
| | Mucin 5AC | 1 | 2020 | 48 | 0.180 |
Why?
| | Metagenomics | 1 | 2021 | 131 | 0.170 |
Why?
| | Gastrointestinal Agents | 1 | 2020 | 60 | 0.170 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 192 | 0.170 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 314 | 0.170 |
Why?
| | Membrane Transport Proteins | 1 | 2020 | 138 | 0.160 |
Why?
| | Receptors, Cannabinoid | 2 | 2017 | 13 | 0.160 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2018 | 12 | 0.160 |
Why?
| | Health Care Costs | 1 | 2021 | 381 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 691 | 0.150 |
Why?
| | Receptors, Interleukin-10 | 1 | 2018 | 6 | 0.150 |
Why?
| | Ambulatory Care | 1 | 2021 | 478 | 0.150 |
Why?
| | Middle Aged | 9 | 2021 | 26827 | 0.150 |
Why?
| | Thrombophilia | 1 | 2018 | 66 | 0.150 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2018 | 70 | 0.150 |
Why?
| | Adult | 11 | 2021 | 30656 | 0.150 |
Why?
| | Male | 13 | 2021 | 55731 | 0.140 |
Why?
| | Interleukin-10 Receptor alpha Subunit | 1 | 2017 | 5 | 0.140 |
Why?
| | Quality of Health Care | 1 | 2021 | 573 | 0.140 |
Why?
| | Thrombelastography | 1 | 2018 | 179 | 0.140 |
Why?
| | Neutrophils | 2 | 2019 | 1164 | 0.140 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 44 | 0.140 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2016 | 14 | 0.140 |
Why?
| | Cannabinoids | 2 | 2017 | 115 | 0.140 |
Why?
| | Nerve Tissue Proteins | 1 | 2020 | 529 | 0.140 |
Why?
| | Hospitalization | 2 | 2022 | 1754 | 0.130 |
Why?
| | Myeloid Cells | 1 | 2017 | 127 | 0.130 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2017 | 144 | 0.130 |
Why?
| | Clostridium Infections | 1 | 2016 | 56 | 0.130 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 29 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 665 | 0.130 |
Why?
| | Inflammasomes | 1 | 2017 | 115 | 0.130 |
Why?
| | Indoles | 1 | 2018 | 304 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2021 | 835 | 0.120 |
Why?
| | Retrospective Studies | 5 | 2022 | 12547 | 0.120 |
Why?
| | Disease Models, Animal | 6 | 2021 | 3545 | 0.120 |
Why?
| | Case-Control Studies | 5 | 2021 | 3015 | 0.120 |
Why?
| | Nausea | 1 | 2014 | 102 | 0.120 |
Why?
| | Steroids | 1 | 2014 | 147 | 0.110 |
Why?
| | Vomiting | 1 | 2014 | 124 | 0.110 |
Why?
| | United States | 4 | 2021 | 12226 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 451 | 0.110 |
Why?
| | Mice | 9 | 2021 | 14927 | 0.110 |
Why?
| | Female | 9 | 2021 | 59613 | 0.100 |
Why?
| | Attitude to Health | 1 | 2016 | 405 | 0.100 |
Why?
| | alpha 1-Antitrypsin | 1 | 2013 | 107 | 0.100 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 12 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 603 | 0.090 |
Why?
| | Administration, Oral | 1 | 2013 | 730 | 0.090 |
Why?
| | Guanine Nucleotides | 1 | 2010 | 15 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1857 | 0.090 |
Why?
| | Thionucleotides | 1 | 2010 | 34 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 299 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4420 | 0.090 |
Why?
| | Methyltransferases | 1 | 2010 | 61 | 0.090 |
Why?
| | Animals | 10 | 2021 | 31867 | 0.080 |
Why?
| | Chronic Disease | 3 | 2022 | 1591 | 0.080 |
Why?
| | Prospective Studies | 3 | 2022 | 6232 | 0.080 |
Why?
| | Genotype | 1 | 2013 | 1780 | 0.080 |
Why?
| | Prognosis | 2 | 2013 | 3334 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 719 | 0.080 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2008 | 26 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2020 | 2585 | 0.070 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 544 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2008 | 68 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2021 | 316 | 0.070 |
Why?
| | Young Adult | 2 | 2013 | 10498 | 0.070 |
Why?
| | Homeostasis | 2 | 2020 | 578 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2011 | 723 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2108 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 4718 | 0.060 |
Why?
| | Prevalence | 1 | 2010 | 2255 | 0.060 |
Why?
| | Cell Line | 2 | 2020 | 2645 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2023 | 143 | 0.050 |
Why?
| | Phosphorylation | 2 | 2021 | 1572 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 92 | 0.050 |
Why?
| | Phenotype | 1 | 2010 | 2815 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 296 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 309 | 0.050 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2021 | 11 | 0.050 |
Why?
| | Cost Savings | 1 | 2021 | 74 | 0.050 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2021 | 28 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 565 | 0.050 |
Why?
| | Granzymes | 1 | 2021 | 40 | 0.050 |
Why?
| | Ileum | 1 | 2021 | 92 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2021 | 164 | 0.050 |
Why?
| | Organoids | 1 | 2021 | 74 | 0.050 |
Why?
| | Adalimumab | 1 | 2020 | 44 | 0.040 |
Why?
| | Protective Factors | 1 | 2020 | 87 | 0.040 |
Why?
| | Azathioprine | 1 | 2020 | 50 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2021 | 2329 | 0.040 |
Why?
| | Models, Economic | 1 | 2020 | 48 | 0.040 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 2019 | 21 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2013 | 9122 | 0.040 |
Why?
| | Leukocyte Disorders | 1 | 2019 | 11 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 101 | 0.040 |
Why?
| | Markov Chains | 1 | 2020 | 114 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 168 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2021 | 278 | 0.040 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2019 | 29 | 0.040 |
Why?
| | Feces | 1 | 2022 | 373 | 0.040 |
Why?
| | Tight Junctions | 1 | 2020 | 68 | 0.040 |
Why?
| | Immune System Diseases | 1 | 2019 | 34 | 0.040 |
Why?
| | Colectomy | 1 | 2020 | 86 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 146 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 247 | 0.040 |
Why?
| | Neutrophil Activation | 1 | 2019 | 94 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 299 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2010 | 6357 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 387 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 285 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2020 | 487 | 0.040 |
Why?
| | Adenosine | 1 | 2019 | 204 | 0.040 |
Why?
| | Child | 2 | 2022 | 18407 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1375 | 0.040 |
Why?
| | Biological Products | 1 | 2020 | 171 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 955 | 0.040 |
Why?
| | Receptors, CCR2 | 1 | 2017 | 28 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 532 | 0.040 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2017 | 39 | 0.030 |
Why?
| | Up-Regulation | 1 | 2019 | 812 | 0.030 |
Why?
| | Child, Preschool | 1 | 2010 | 9093 | 0.030 |
Why?
| | Biopsy | 1 | 2020 | 1046 | 0.030 |
Why?
| | Kynurenine | 1 | 2017 | 80 | 0.030 |
Why?
| | Signal Transduction | 2 | 2021 | 4525 | 0.030 |
Why?
| | Hematopoiesis | 1 | 2017 | 172 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2019 | 481 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2318 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2020 | 729 | 0.030 |
Why?
| | Antibodies | 1 | 2017 | 372 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 370 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2017 | 297 | 0.030 |
Why?
| | Mitochondria | 1 | 2020 | 750 | 0.030 |
Why?
| | Wound Healing | 1 | 2017 | 259 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1523 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2020 | 956 | 0.030 |
Why?
| | Bacteria | 1 | 2020 | 728 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 503 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1747 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2017 | 723 | 0.030 |
Why?
| | Nanoparticles | 1 | 2017 | 313 | 0.030 |
Why?
| | Base Sequence | 1 | 2017 | 2119 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 83 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1133 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 4904 | 0.030 |
Why?
| | Aged | 1 | 2010 | 19119 | 0.030 |
Why?
| | Adolescent | 1 | 2010 | 17864 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2019 | 3896 | 0.030 |
Why?
| | Pancreatic Neoplasms | 1 | 2018 | 722 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6141 | 0.020 |
Why?
| | Granulocytes | 1 | 2011 | 77 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 915 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 140 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1084 | 0.020 |
Why?
| | ROC Curve | 1 | 2011 | 447 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2011 | 174 | 0.020 |
Why?
| | Down-Regulation | 1 | 2011 | 599 | 0.020 |
Why?
| | HeLa Cells | 1 | 2008 | 562 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1812 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 1843 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 344 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2011 | 2563 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2551 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4089 | 0.010 |
Why?
| | Biomarkers | 1 | 2011 | 3419 | 0.010 |
Why?
|
|
Gerich's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|